Adial Pharmaceuticals Adjourns Votes Pending Nasdaq Listing Approval
Adial Pharmaceuticals has adjourned votes on four proposals due to pending Nasdaq listing approval. The meeting has been reconvened for October 15, 2026.
Adial Pharmaceuticals has adjourned votes on four proposals due to pending Nasdaq listing approval. The meeting has been reconvened for October 15, 2026.